69 related articles for article (PubMed ID: 30440160)
1. [The genetic factors of non-response to anti-vascular endothelial growth factor therapy].
Xu SX; Huang SW; Su GF
Zhonghua Yan Ke Za Zhi; 2018 Nov; 54(11):873-878. PubMed ID: 30440160
[TBL] [Abstract][Full Text] [Related]
2. Defining response to anti-VEGF therapies in neovascular AMD.
Amoaku WM; Chakravarthy U; Gale R; Gavin M; Ghanchi F; Gibson J; Harding S; Johnston RL; Kelly SP; Lotery A; Mahmood S; Menon G; Sivaprasad S; Talks J; Tufail A; Yang Y
Eye (Lond); 2015 Jun; 29(6):721-31. PubMed ID: 25882328
[TBL] [Abstract][Full Text] [Related]
3. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.
Kloeckener-Gruissem B; Barthelmes D; Labs S; Schindler C; Kurz-Levin M; Michels S; Fleischhauer J; Berger W; Sutter F; Menghini M
Invest Ophthalmol Vis Sci; 2011 Jul; 52(7):4694-702. PubMed ID: 21282580
[TBL] [Abstract][Full Text] [Related]
4. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration.
Finger RP; Wickremasinghe SS; Baird PN; Guymer RH
Surv Ophthalmol; 2014; 59(1):1-18. PubMed ID: 24332379
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.
Chen G; Tzekov R; Li W; Jiang F; Mao S; Tong Y
Sci Rep; 2015 Sep; 5():14517. PubMed ID: 26411831
[TBL] [Abstract][Full Text] [Related]
6. The presence of CFH, HTRA1, ARMS2, VEGF-A and VEGF-R and the appearance of age-related macular degeneration sub-types.
Cruz-González F; Cabrillo Estévez L; Cañete Campos C; Sánchez-Jara Sánchez A; Juan Marcos L; González-Sarmiento R
Arch Soc Esp Oftalmol; 2016 Apr; 91(4):177-83. PubMed ID: 26850328
[TBL] [Abstract][Full Text] [Related]
7. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
Kubicka-Trząska A; Karska-Basta I; Kobylarz J; Dziedzina S; Sanak M; Romanowska-Dixon B
Klin Oczna; 2016; 118(2):114-21. PubMed ID: 29912491
[TBL] [Abstract][Full Text] [Related]
8. Effect of Risk Alleles in CFH, C3, and VEGFA on the Response to Intravitreal Bevacizumab in Tunisian Patients with Neovascular Age-related Macular Degeneration.
Habibi I; Kort F; Sfar I; Chebil A; Bouraoui R; Ben Abdallah T; Gorgi Y; El Matri L
Klin Monbl Augenheilkd; 2016 Apr; 233(4):465-70. PubMed ID: 27116510
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacogenetics and age-related macular degeneration, towards an individualized treatment of the disease].
Cruz-González F; Cabrillo Estévez L; López-Valverde G; Escudero-Domínguez F; González-Sarmiento R
Arch Soc Esp Oftalmol; 2013 Oct; 88(10):371-2. PubMed ID: 24060299
[No Abstract] [Full Text] [Related]
10. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
[TBL] [Abstract][Full Text] [Related]
11. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.
Tian J; Qin X; Fang K; Chen Q; Hou J; Li J; Yu W; Chen D; Hu Y; Li X
Pharmacogenomics; 2012 May; 13(7):779-87. PubMed ID: 22594510
[TBL] [Abstract][Full Text] [Related]
12. LOC387715/HTRA1 variants and the response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Park DH; Kim IT
Retina; 2012 Feb; 32(2):299-307. PubMed ID: 21817962
[TBL] [Abstract][Full Text] [Related]
13. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.
Boltz A; Ruiß M; Jonas JB; Tao Y; Rensch F; Weger M; Garhöfer G; Frantal S; El-Shabrawi Y; Schmetterer L
Ophthalmology; 2012 Aug; 119(8):1615-20. PubMed ID: 22521084
[TBL] [Abstract][Full Text] [Related]
14. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia.
Miyake M; Yamashiro K; Akagi-Kurashige Y; Kumagai K; Nakata I; Nakanishi H; Oishi A; Tsujikawa A; Yamada R; Matsuda F; Yoshimura N
Ophthalmology; 2014 Jan; 121(1):225-233. PubMed ID: 23953100
[TBL] [Abstract][Full Text] [Related]
17. Association of ARMS2 genotype with response to anti-vascular endothelial growth factor treatment in polypoidal choroidal vasculopathy.
Park UC; Shin JY; Chung H; Yu HG
BMC Ophthalmol; 2017 Dec; 17(1):241. PubMed ID: 29212537
[TBL] [Abstract][Full Text] [Related]
18. IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.
Lazzeri S; Orlandi P; Piaggi P; Sartini MS; Casini G; Guidi G; Figus M; Fioravanti A; Di Desidero T; Ripandelli G; Parravano M; Varano M; Nardi M; Bocci G
Pharmacogenomics; 2016; 17(1):35-9. PubMed ID: 26653034
[TBL] [Abstract][Full Text] [Related]
19. VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration.
Veloso CE; de Almeida LN; Recchia FM; Pelayes D; Nehemy MB
Ophthalmic Res; 2014; 51(1):1-8. PubMed ID: 24157918
[TBL] [Abstract][Full Text] [Related]
20. Receiver operating characteristic curve to predict anti-VEGF resistance in retinal vein occlusions and efficacy of Ozurdex.
Wolfe JD; Shah AR; Yonekawa Y; Al Faran A; Franklin MS; Abbey AM; Capone A
Eur J Ophthalmol; 2016; 26(2):168-73. PubMed ID: 26428221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
